Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads...
Gespeichert in:
| Veröffentlicht in: | Oncoimmunology 2018-03, Vol.7 (3), p.e1395127 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | e1395127 |
| container_title | Oncoimmunology |
| container_volume | 7 |
| creator | Hoffmann, Ricarda M. Coumbe, Ben G. T. Josephs, Debra H. Mele, Silvia Ilieva, Kristina M. Cheung, Anthony Tutt, Andrew N. Spicer, James F. Thurston, David E. Crescioli, Silvia Karagiannis, Sophia N. |
| description | Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs. |
| doi_str_mv | 10.1080/2162402X.2017.1395127 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5769674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5d2494482e864414bfd81f737138fa2c</doaj_id><sourcerecordid>29375935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c600t-1963f302eac17c2fc916532382560a25fa750168e7106d420b7bd79d7d0336423</originalsourceid><addsrcrecordid>eNp9kUtPGzEUhUdVUUHAT2jlZbtI6rfHm6pRaAEJiQ2VurM8fgyOJnZke6jy7ztDICqbeuOre8757uI0zUcElwi28CtGHFOIfy8xRGKJiGQIi3fN2bxfzML744zQaXNZygZOj0PGifzQnGJJBJOEnTW7VayhS3YPSs2jqWN2QEcLXOxDdC6H2AOTYgnWZV3DNAGfMqiPDlhXQh-f3X6MZhZB8uAIvMpjD9YpbsZeV1fA59XVuny5aE68Hoq7fPnPm18_fzysbxZ399e369XdwnAI6wJJTjyB2GmDhMHeSMQZwaTFjEONmdeCQcRbJxDklmLYic4KaYWFhHCKyXlze-DapDdql8NW571KOqjnRcq90rkGMzjFLKaS0ha7llOKaOdti7wgApHWa2wm1rcDazd2W2eNizXr4Q30rRLDo-rTk2KCSy7oBGAHgMmplOz8MYugmhtVr42quVH10uiU-_Tv4WPqtb_J8P1gCHGqZav_pDxYVfV-SNlnHU0oivz_xl9357Bi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)</title><source>PubMed Central</source><creator>Hoffmann, Ricarda M. ; Coumbe, Ben G. T. ; Josephs, Debra H. ; Mele, Silvia ; Ilieva, Kristina M. ; Cheung, Anthony ; Tutt, Andrew N. ; Spicer, James F. ; Thurston, David E. ; Crescioli, Silvia ; Karagiannis, Sophia N.</creator><creatorcontrib>Hoffmann, Ricarda M. ; Coumbe, Ben G. T. ; Josephs, Debra H. ; Mele, Silvia ; Ilieva, Kristina M. ; Cheung, Anthony ; Tutt, Andrew N. ; Spicer, James F. ; Thurston, David E. ; Crescioli, Silvia ; Karagiannis, Sophia N.</creatorcontrib><description>Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2017.1395127</identifier><identifier>PMID: 29375935</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antibodies ; Antibody Drug Conjugate (ADC) ; biodistribution ; effector functions ; IgG1 ; IgG4 ; Immunoglobulin Fc ; kinetics ; Review ; stability</subject><ispartof>Oncoimmunology, 2018-03, Vol.7 (3), p.e1395127</ispartof><rights>2018 The Author(s). Published with license by Taylor & Francis Group, LLC © Ricarda M. Hoffmann, Ben G. T. Coumbe, Debra H. Josephs, Silvia Mele, Kristina M. Ilieva, Anthony Cheung, Andrew N. Tutt, James F. Spicer, David E. Thurston, Silvia Crescioli, and Sophia N. Karagiannis 2018</rights><rights>2018 The Author(s). Published with license by Taylor & Francis Group, LLC 2018 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c600t-1963f302eac17c2fc916532382560a25fa750168e7106d420b7bd79d7d0336423</citedby><cites>FETCH-LOGICAL-c600t-1963f302eac17c2fc916532382560a25fa750168e7106d420b7bd79d7d0336423</cites><orcidid>0000-0002-4100-7810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769674/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769674/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29375935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffmann, Ricarda M.</creatorcontrib><creatorcontrib>Coumbe, Ben G. T.</creatorcontrib><creatorcontrib>Josephs, Debra H.</creatorcontrib><creatorcontrib>Mele, Silvia</creatorcontrib><creatorcontrib>Ilieva, Kristina M.</creatorcontrib><creatorcontrib>Cheung, Anthony</creatorcontrib><creatorcontrib>Tutt, Andrew N.</creatorcontrib><creatorcontrib>Spicer, James F.</creatorcontrib><creatorcontrib>Thurston, David E.</creatorcontrib><creatorcontrib>Crescioli, Silvia</creatorcontrib><creatorcontrib>Karagiannis, Sophia N.</creatorcontrib><title>Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.</description><subject>Antibodies</subject><subject>Antibody Drug Conjugate (ADC)</subject><subject>biodistribution</subject><subject>effector functions</subject><subject>IgG1</subject><subject>IgG4</subject><subject>Immunoglobulin Fc</subject><subject>kinetics</subject><subject>Review</subject><subject>stability</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUtPGzEUhUdVUUHAT2jlZbtI6rfHm6pRaAEJiQ2VurM8fgyOJnZke6jy7ztDICqbeuOre8757uI0zUcElwi28CtGHFOIfy8xRGKJiGQIi3fN2bxfzML744zQaXNZygZOj0PGifzQnGJJBJOEnTW7VayhS3YPSs2jqWN2QEcLXOxDdC6H2AOTYgnWZV3DNAGfMqiPDlhXQh-f3X6MZhZB8uAIvMpjD9YpbsZeV1fA59XVuny5aE68Hoq7fPnPm18_fzysbxZ399e369XdwnAI6wJJTjyB2GmDhMHeSMQZwaTFjEONmdeCQcRbJxDklmLYic4KaYWFhHCKyXlze-DapDdql8NW571KOqjnRcq90rkGMzjFLKaS0ha7llOKaOdti7wgApHWa2wm1rcDazd2W2eNizXr4Q30rRLDo-rTk2KCSy7oBGAHgMmplOz8MYugmhtVr42quVH10uiU-_Tv4WPqtb_J8P1gCHGqZav_pDxYVfV-SNlnHU0oivz_xl9357Bi</recordid><startdate>20180304</startdate><enddate>20180304</enddate><creator>Hoffmann, Ricarda M.</creator><creator>Coumbe, Ben G. T.</creator><creator>Josephs, Debra H.</creator><creator>Mele, Silvia</creator><creator>Ilieva, Kristina M.</creator><creator>Cheung, Anthony</creator><creator>Tutt, Andrew N.</creator><creator>Spicer, James F.</creator><creator>Thurston, David E.</creator><creator>Crescioli, Silvia</creator><creator>Karagiannis, Sophia N.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4100-7810</orcidid></search><sort><creationdate>20180304</creationdate><title>Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)</title><author>Hoffmann, Ricarda M. ; Coumbe, Ben G. T. ; Josephs, Debra H. ; Mele, Silvia ; Ilieva, Kristina M. ; Cheung, Anthony ; Tutt, Andrew N. ; Spicer, James F. ; Thurston, David E. ; Crescioli, Silvia ; Karagiannis, Sophia N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c600t-1963f302eac17c2fc916532382560a25fa750168e7106d420b7bd79d7d0336423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibodies</topic><topic>Antibody Drug Conjugate (ADC)</topic><topic>biodistribution</topic><topic>effector functions</topic><topic>IgG1</topic><topic>IgG4</topic><topic>Immunoglobulin Fc</topic><topic>kinetics</topic><topic>Review</topic><topic>stability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffmann, Ricarda M.</creatorcontrib><creatorcontrib>Coumbe, Ben G. T.</creatorcontrib><creatorcontrib>Josephs, Debra H.</creatorcontrib><creatorcontrib>Mele, Silvia</creatorcontrib><creatorcontrib>Ilieva, Kristina M.</creatorcontrib><creatorcontrib>Cheung, Anthony</creatorcontrib><creatorcontrib>Tutt, Andrew N.</creatorcontrib><creatorcontrib>Spicer, James F.</creatorcontrib><creatorcontrib>Thurston, David E.</creatorcontrib><creatorcontrib>Crescioli, Silvia</creatorcontrib><creatorcontrib>Karagiannis, Sophia N.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffmann, Ricarda M.</au><au>Coumbe, Ben G. T.</au><au>Josephs, Debra H.</au><au>Mele, Silvia</au><au>Ilieva, Kristina M.</au><au>Cheung, Anthony</au><au>Tutt, Andrew N.</au><au>Spicer, James F.</au><au>Thurston, David E.</au><au>Crescioli, Silvia</au><au>Karagiannis, Sophia N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2018-03-04</date><risdate>2018</risdate><volume>7</volume><issue>3</issue><spage>e1395127</spage><pages>e1395127-</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>29375935</pmid><doi>10.1080/2162402X.2017.1395127</doi><orcidid>https://orcid.org/0000-0002-4100-7810</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-4011 |
| ispartof | Oncoimmunology, 2018-03, Vol.7 (3), p.e1395127 |
| issn | 2162-4011 2162-402X 2162-402X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5769674 |
| source | PubMed Central |
| subjects | Antibodies Antibody Drug Conjugate (ADC) biodistribution effector functions IgG1 IgG4 Immunoglobulin Fc kinetics Review stability |
| title | Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A13%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20structure%20and%20engineering%20considerations%20for%20the%20design%20and%20function%20of%20Antibody%20Drug%20Conjugates%20(ADCs)&rft.jtitle=Oncoimmunology&rft.au=Hoffmann,%20Ricarda%20M.&rft.date=2018-03-04&rft.volume=7&rft.issue=3&rft.spage=e1395127&rft.pages=e1395127-&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2017.1395127&rft_dat=%3Cpubmed_infor%3E29375935%3C/pubmed_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29375935&rft_doaj_id=oai_doaj_org_article_5d2494482e864414bfd81f737138fa2c&rfr_iscdi=true |